Want to see CSBR full AI Analyst Report?
Revenue By Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.Revenue is highly concentrated in Pharmacology Services, which produced the recent rebound but still moves in lumpy, project‑timing waves; Other TOS has declined materially since 2024 and Personalized Oncology is effectively immaterial, so true diversification is lacking. A large, irregular TOS license payment in 2025 created a one‑off bump that masks the underlying softness. Investors should view near‑term performance as dependent on repeat pharmacology bookings rather than stable, diversified streams.
Date | Pharmacology Services | Personalized Oncology Services | Other TOS | TOS License |
|---|---|---|---|---|
Jul 31, 2026 | $14.16M | $0.00 | $183.00K | $893.00K |
Apr 30, 2026 | $13.20M | $0.00 | $336.00K | $296.00K |
Jan 31, 2026 | $16.18M | $0.00 | $375.00K | $0.00 |
Oct 31, 2025 | $14.52M | $0.00 | $363.00K | $157.00K |
Jul 31, 2025 | $13.23M | $0.00 | $454.00K | $311.00K |
Apr 30, 2025 | $11.35M | $0.00 | $831.00K | $176.00K |
Jan 31, 2025 | $11.67M | $0.00 | $869.00K | $4.50M |
Oct 31, 2024 | $12.50M | $0.00 | $991.00K | $0.00 |
Jul 31, 2024 | $13.07M | $0.00 | $992.00K | $0.00 |
Apr 30, 2024 | $13.12M | $1.00K | $886.00K | $0.00 |